Pro-Pharmaceuticals (PRW) Reports Positive Phase II Data of DAVANAT in Combination with 5-fluorouracil
More News related to PRW
- Pro-Pharmaceuticals (PRW) Anticipates Listing on Bulletin Board; Releases President and Chief Scientist
- Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
- Pro-Pharmaceuticals (PRW) Announces FDA Approves IND For Use of DAVANAT
- Pro-Pharmaceuticals (PRW) Reports Positive Phase II Data of DAVANAT in Combination with 5-fluorouracil
- Pro-Pharmaceuticals (PRW) Receives Non-Compliance Notification From AMEX
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Pro-Pharmaceuticals, Inc. (Amex: PRW) announced that data of all end-stage colorectal cancer patients from its Phase II trial showed DAVANAT, administered in combination with 5-fluorouracil (5-FU), extended median survival by 6.7 months or 29 weeks after all other treatments were exhausted. The data for the 20 patients that completed the trial revealed that three patients survived more than one year, two patients survived more than two years and one patient is still alive.
The data also revealed significantly reduced levels of toxicity as measured by serious adverse events (SAEs). The patients from the Phase II trial experienced total SAEs of 35% with only 10% drug related, compared with more than 70% SAEs reported for similar patient populations in similar trials. Additionally, the data showed no apparent change from the baseline measurements in all clinical parameters including platelets and white blood cell counts. Safety data indicates improved quality of life.
Related Categories
Corporate NewsStocks Mentioned
+0.00Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
PRW
CapeCod Dan Investor on Dec 3, 2008 01:07 PMFingers crossed, but I believe in them.